CytomX Therapeutics, Inc. (NASDAQ:CTMX) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Monday.
Other research analysts have also issued reports about the company. HC Wainwright started coverage on CytomX Therapeutics in a research report on Monday, March 27th. They issued a “buy” rating and a $24.00 target price on the stock. Cowen and Company reissued a “buy” rating on shares of CytomX Therapeutics in a report on Wednesday, June 28th. Jefferies Group LLC reissued a “buy” rating and set a $25.00 price objective on shares of CytomX Therapeutics in a report on Tuesday, June 6th. Zacks Investment Research raised CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a report on Wednesday, May 3rd. Finally, Cann reissued a “hold” rating on shares of CytomX Therapeutics in a report on Thursday, March 30th. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $24.50.
CytomX Therapeutics (NASDAQ CTMX) traded up 2.21% during trading on Monday, reaching $13.88. The company had a trading volume of 138,275 shares. CytomX Therapeutics has a 12 month low of $9.81 and a 12 month high of $20.02. The stock has a 50 day moving average of $14.72 and a 200-day moving average of $14.26. The company’s market capitalization is $510.08 million.
CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Friday, May 5th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.32. CytomX Therapeutics had a negative return on equity of 59.65% and a negative net margin of 208.92%. The company had revenue of $11.65 million for the quarter, compared to analyst estimates of $2.10 million. Equities research analysts expect that CytomX Therapeutics will post ($1.41) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was first reported by BBNS and is the property of of BBNS. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://baseballnewssource.com/markets/bidaskclub-lowers-cytomx-therapeutics-inc-ctmx-to-sell/1270514.html.
In other news, insider Sean A. Mccarthy sold 4,781 shares of the stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $15.52, for a total transaction of $74,201.12. Following the transaction, the insider now owns 9,026 shares of the company’s stock, valued at approximately $140,083.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Debanjan Ray sold 2,500 shares of the stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $15.47, for a total value of $38,675.00. Following the transaction, the chief financial officer now directly owns 22,126 shares in the company, valued at approximately $342,289.22. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,843 shares of company stock worth $572,703. 8.00% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. First Quadrant L P CA bought a new position in shares of CytomX Therapeutics during the second quarter worth approximately $160,000. Goldman Sachs Group Inc. acquired a new stake in shares of CytomX Therapeutics during the first quarter valued at $190,000. Driehaus Capital Management LLC acquired a new stake in shares of CytomX Therapeutics during the first quarter valued at $5,089,000. HarbourVest Partners LLC increased its stake in shares of CytomX Therapeutics by 150.0% in the first quarter. HarbourVest Partners LLC now owns 25,000 shares of the biotechnology company’s stock valued at $432,000 after buying an additional 15,000 shares during the last quarter. Finally, Iguana Healthcare Management LLC acquired a new stake in shares of CytomX Therapeutics during the first quarter valued at $1,295,000. 52.28% of the stock is currently owned by institutional investors and hedge funds.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with our FREE daily email newsletter.